RE:RE:Random things, from AGM informationPfizer and any other Big Pharma company with an immune checkpoint inhibitor that would benefit from being combined with ONCY's pelareorep are all potential acquirers of ONCY.
Aside from Pfizer developing its own PD-1 checkpoint inhibitor in sasanlimab, Pfizer's intended $43 Billion acquisition of Seagen may not receive the approval of the FTC as I had posted recently, since they reversed their earlier decision on the $8 Billion take-over of Grail.
Therefore nothing is off-the-table, whixh is contrary to what you have tried to suggest.